Key Points
- Glaukos CFO Alex Thurman sold 10,000 shares on April 30 at an average price of $140 under a pre-arranged Rule 10b5-1 plan, a transaction of $1.4 million that reduced his stake by 18.63% to 43,681 shares.
- Quarterly results beat expectations: Glaukos reported EPS of ($0.18) vs. an expected ($0.30) and revenue of $150.57 million (up 41.2% year-over-year) vs. $137 million expected.
- Analyst sentiment is mostly positive with an average price target of about $138.85 and multiple recent upgrades from firms like JPMorgan and Citigroup, contributing to a consensus "Moderate Buy" rating.
Glaukos Corporation (NYSE:GKOS - Get Free Report) Director Leana Wen sold 1,700 shares of the business's stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $143.35, for a total value of $243,695.00. Following the sale, the director owned 19,739 shares in the company, valued at approximately $2,829,585.65. This represents a 7.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Glaukos Stock Performance
GKOS opened at $135.98 on Tuesday. The stock has a market cap of $7.99 billion, a PE ratio of -41.46 and a beta of 0.94. The company has a current ratio of 5.43, a quick ratio of 4.73 and a debt-to-equity ratio of 0.10. Glaukos Corporation has a 1 year low of $73.16 and a 1 year high of $146.75. The stock's 50 day simple moving average is $114.02 and its 200-day simple moving average is $108.01.
Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.30) by $0.12. The business had revenue of $150.57 million for the quarter, compared to analysts' expectations of $137.00 million. Glaukos had a negative return on equity of 6.92% and a negative net margin of 34.34%.Glaukos's quarterly revenue was up 41.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.22) earnings per share. Sell-side analysts forecast that Glaukos Corporation will post -0.6 EPS for the current year.
Institutional Trading of Glaukos
Large investors have recently made changes to their positions in the business. Smartleaf Asset Management LLC lifted its stake in shares of Glaukos by 9.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier's stock valued at $158,000 after acquiring an additional 122 shares during the period. Larson Financial Group LLC lifted its stake in shares of Glaukos by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier's stock valued at $39,000 after acquiring an additional 132 shares during the period. CWM LLC lifted its stake in shares of Glaukos by 25.2% during the fourth quarter. CWM LLC now owns 710 shares of the medical instruments supplier's stock valued at $80,000 after acquiring an additional 143 shares during the period. Commonwealth Equity Services LLC lifted its stake in shares of Glaukos by 1.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier's stock valued at $947,000 after acquiring an additional 144 shares during the period. Finally, Evergreen Capital Management LLC lifted its stake in shares of Glaukos by 4.3% during the fourth quarter. Evergreen Capital Management LLC now owns 3,549 shares of the medical instruments supplier's stock valued at $401,000 after acquiring an additional 145 shares during the period. Institutional investors own 99.04% of the company's stock.
Wall Street Analyst Weigh In
A number of analysts have recently issued reports on the company. Piper Sandler restated an "overweight" rating and set a $165.00 price objective on shares of Glaukos in a research report on Wednesday, January 14th. The Goldman Sachs Group restated a "buy" rating and set a $138.00 price objective on shares of Glaukos in a research report on Friday, January 9th. Stifel Nicolaus set a $170.00 price target on Glaukos in a research report on Thursday. Citigroup upped their price target on Glaukos from $135.00 to $140.00 and gave the company a "buy" rating in a research report on Thursday. Finally, Wells Fargo & Company upped their price target on Glaukos from $135.00 to $138.00 and gave the company an "overweight" rating in a research report on Thursday, April 30th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $138.85.
Read Our Latest Analysis on GKOS
Glaukos Company Profile
(
Get Free Report)
Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company's core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos's flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.
Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
